Syqe Medical is developing a precision dosing system for cannabis and psychoactive botanicals, enabling their transformation into standardized medical treatments. This technology addresses the inconsistency in dosing and efficacy of these substances, facilitating their acceptance in mainstream healthcare.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of administering cannabis and other psychoactive botanicals lack precision, leading to inconsistent dosing and variable therapeutic effects. This variability hinders their acceptance and integration into mainstream medical treatments.
Solution
Syqe Medical is developing a metered-dose inhaler (MDI) technology designed to deliver precise and consistent doses of cannabis and other psychoactive botanicals. This system aims to overcome the challenges associated with traditional methods of consumption, such as smoking or edibles, which can result in unpredictable absorption rates and inconsistent effects. By providing a standardized and controlled delivery mechanism, Syqe Medical seeks to transform these substances into reliable and predictable medical treatments. The technology is intended to improve patient outcomes by ensuring accurate dosing and minimizing the risk of adverse effects.
Target Audience
The primary target audience includes patients requiring medical cannabis or other psychoactive botanicals for therapeutic purposes, as well as healthcare professionals seeking reliable and standardized treatment options.
Features
- Metered-dose inhaler (MDI) technology for precise and consistent dosing
- Standardized delivery mechanism to ensure predictable absorption rates
- Controlled administration to minimize variability in therapeutic effects